The Impact of PAI-1 Gene Polymorphisms on the Efficacy of Tezepelumab
Not Applicable
- Conditions
- Bronchial Asthma
- Registration Number
- JPRN-UMIN000052531
- Lead Sponsor
- agasaki University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
Exclusion criteria 1) Patients treated with bronchial thermoplasty 2) Patients with comorbidities requiring systemic steroids or immunosuppressive agents (except when systemic steroids are used as maintenance therapy for asthma) 3) Patients who are deemed inappropriate as research subjects by the investigator.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary outcome of this study is the annual exacerbation rate from the beginning of treatment to one year later, and the secondary outcomes include the Asthma Control Questionnaire-6, pulmonary function tests (FEV1, PEF), exhaled nitric oxide levels, peripheral blood eosinophil count, and total IgE levels at 84 weeks and one year after treatment initiation.
- Secondary Outcome Measures
Name Time Method